{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,18]],"date-time":"2026-08-18T02:34:41Z","timestamp":1787020481310,"version":"build-2736575974"},"reference-count":38,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,3,3]],"date-time":"2026-03-03T00:00:00Z","timestamp":1772496000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,4,8]],"date-time":"2026-04-08T00:00:00Z","timestamp":1775606400000},"content-version":"vor","delay-in-days":36,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82170217"],"award-info":[{"award-number":["82170217"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82070192"],"award-info":[{"award-number":["82070192"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Noncommunicable Chronic Diseases-National Science and Technology Major Project","award":["2023ZD0502400"],"award-info":[{"award-number":["2023ZD0502400"]}]},{"DOI":"10.13039\/501100012166","name":"National Key R&D Program of China","doi-asserted-by":"crossref","award":["2023YFC2508902"],"award-info":[{"award-number":["2023YFC2508902"]}],"id":[{"id":"10.13039\/501100012166","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Med"],"DOI":"10.1186\/s12916-026-04744-9","type":"journal-article","created":{"date-parts":[[2026,3,3]],"date-time":"2026-03-03T01:06:28Z","timestamp":1772499988000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Day\u2009+\u200930 detection of minimal residual FLT3-ITD by high-sensitivity PCR-NGS predicts relapse risk and guides post-transplant maintenance in AML"],"prefix":"10.1186","volume":"24","author":[{"given":"Shan","family":"Jiang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dan","family":"Feng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Li","family":"Wan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nan","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jiao","family":"Ma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jiaxin","family":"Cao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pan","family":"Pan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yawei","family":"Zheng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yigeng","family":"Cao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wenbin","family":"Cao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chen","family":"Liang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xin","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rongli","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qiaoling","family":"Ma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jialin","family":"Wei","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Weihua","family":"Zhai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Donglin","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yi","family":"He","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sizhou","family":"Feng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mingzhe","family":"Han","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yao","family":"Yao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aiming","family":"Pang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Erlie","family":"Jiang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,3,3]]},"reference":[{"key":"4744_CR1","doi-asserted-by":"publisher","first-page":"22812","DOI":"10.18632\/oncotarget.4333","volume":"6","author":"J-E Bibault","year":"2015","unstructured":"Bibault J-E, Figeac M, H\u00e9levaut N, Rodriguez C, Quief S, Sebda S, et al. Next-generation sequencing of FLT3 internal tandem duplications for minimal residual disease monitoring in acute myeloid leukemia. Oncotarget. 2015;6:22812\u201321.","journal-title":"Oncotarget"},{"key":"4744_CR2","doi-asserted-by":"publisher","first-page":"934","DOI":"10.1200\/JCO.2016.71.2208","volume":"35","author":"L Bullinger","year":"2017","unstructured":"Bullinger L, D\u00f6hner K, D\u00f6hner H. Genomics of acute myeloid leukemia diagnosis and pathways. J Clin Oncol. 2017;35:934\u201346. https:\/\/doi.org\/10.1200\/JCO.2016.71.2208.","journal-title":"J Clin Oncol"},{"key":"4744_CR3","doi-asserted-by":"publisher","first-page":"299","DOI":"10.1038\/s41375-018-0357-9","volume":"33","author":"N Daver","year":"2019","unstructured":"Daver N, Schlenk RF, Russell NH, Levis MJ. Targeting FLT3 mutations in AML: review of current knowledge and evidence. Leukemia. 2019;33:299\u2013312. https:\/\/doi.org\/10.1038\/s41375-018-0357-9.","journal-title":"Leukemia"},{"key":"4744_CR4","doi-asserted-by":"publisher","first-page":"4326","DOI":"10.1182\/blood.v99.12.4326","volume":"99","author":"C Thiede","year":"2002","unstructured":"Thiede C, Steudel C, Mohr B, Schaich M, Sch\u00e4kel U, Platzbecker U, et al. Analysis of FLT3-activating mutations in 979 patients with acute myelogenous leukemia: association with FAB subtypes and identification of subgroups with poor prognosis. Blood. 2002;99:4326\u201335. https:\/\/doi.org\/10.1182\/blood.v99.12.4326.","journal-title":"Blood"},{"key":"4744_CR5","doi-asserted-by":"publisher","first-page":"30128","DOI":"10.18632\/oncotarget.25729","volume":"9","author":"K Schranz","year":"2018","unstructured":"Schranz K, Hubmann M, Harin E, Vosberg S, Herold T, Metzeler KH, et al. Clonal heterogeneity of FLT3-ITD detected by high-throughput amplicon sequencing correlates with adverse prognosis in acute myeloid leukemia. Oncotarget. 2018;9:30128\u201345. https:\/\/doi.org\/10.18632\/oncotarget.25729.","journal-title":"Oncotarget"},{"key":"4744_CR6","doi-asserted-by":"publisher","first-page":"371","DOI":"10.1182\/blood.2019002697","volume":"135","author":"K D\u00f6hner","year":"2020","unstructured":"D\u00f6hner K, Thiede C, Jahn N, Panina E, Gambietz A, Larson RA, et al. Impact of NPM1\/FLT3-ITD genotypes defined by the 2017 European LeukemiaNet in patients with acute myeloid leukemia. Blood. 2020;135:371\u201380. https:\/\/doi.org\/10.1182\/blood.2019002697.","journal-title":"Blood"},{"key":"4744_CR7","doi-asserted-by":"publisher","first-page":"422","DOI":"10.1056\/NEJMoa1507471","volume":"374","author":"A Ivey","year":"2016","unstructured":"Ivey A, Hills RK, Simpson MA, Jovanovic JV, Gilkes A, Grech A, et al. Assessment of minimal residual disease in standard-risk AML. N Engl J Med. 2016;374:422\u201333. https:\/\/doi.org\/10.1056\/NEJMoa1507471.","journal-title":"N Engl J Med"},{"key":"4744_CR8","doi-asserted-by":"publisher","first-page":"4048","DOI":"10.1200\/JCO.22.00602","volume":"40","author":"N Daver","year":"2022","unstructured":"Daver N, Perl AE, Maly J, Levis M, Ritchie E, Litzow M, et al. <article-title update=\"added\"> Venetoclax Plus Gilteritinib for FLT3 -Mutated Relapsed\/Refractory Acute Myeloid Leukemia. J Clin Oncol. 2022;40:4048\u201359. https:\/\/doi.org\/10.1200\/JCO.22.00602.","journal-title":"J Clin Oncol"},{"key":"4744_CR9","doi-asserted-by":"publisher","first-page":"1499","DOI":"10.1200\/JCO.23.01911","volume":"42","author":"NJ Short","year":"2024","unstructured":"Short NJ, Daver N, Dinardo CD, Kadia T, Nasr LF, Macaron W, et al. Azacitidine, venetoclax, and gilteritinib in newly diagnosed and relapsed or refractory FLT3-mutated AML. J Clin Oncol. 2024;42:1499\u2013508. https:\/\/doi.org\/10.1200\/JCO.23.01911.","journal-title":"J Clin Oncol"},{"key":"4744_CR10","doi-asserted-by":"publisher","first-page":"1462","DOI":"10.1038\/s41409-019-0456-x","volume":"54","author":"Y-Y Zhang","year":"2019","unstructured":"Zhang Y-Y, Mo X-D, Zhang X-H, Xu L-P, Wang Y, Yan C-H, et al. FLT3 internal tandem duplication does not impact prognosis after haploidentical allogeneic hematopoietic stem cell transplantation in AML patients. Bone Marrow Transplant. 2019;54:1462\u201370. https:\/\/doi.org\/10.1038\/s41409-019-0456-x.","journal-title":"Bone Marrow Transplant"},{"key":"4744_CR11","doi-asserted-by":"publisher","DOI":"10.1038\/s41392-023-01614-1","volume":"8","author":"R Shao","year":"2023","unstructured":"Shao R, Zhang Y, He J, Huang F, Fan Z, Yang K, et al. Impact of genetic patterns on sorafenib efficacy in patients with FLT3-ITD acute myeloid leukemia undergoing allogeneic hematopoietic stem cell transplantation: a multi-center, cohort study. Signal Transduct Target Ther. 2023;8:348. https:\/\/doi.org\/10.1038\/s41392-023-01614-1.","journal-title":"Signal Transduct Target Ther"},{"key":"4744_CR12","doi-asserted-by":"publisher","first-page":"e600","DOI":"10.1016\/S2352-3026(23)00117-5","volume":"10","author":"L Xuan","year":"2023","unstructured":"Xuan L, Wang Y, Yang K, Shao R, Huang F, Fan Z, et al. Sorafenib maintenance after allogeneic haemopoietic stem-cell transplantation in patients with FLT3-ITD acute myeloid leukaemia: long-term follow-up of an open-label, multicentre, randomised, phase 3 trial. Lancet Haematol. 2023;10:e600\u201311. https:\/\/doi.org\/10.1016\/S2352-3026(23)00117-5.","journal-title":"Lancet Haematol"},{"key":"4744_CR13","doi-asserted-by":"publisher","first-page":"1931","DOI":"10.1182\/blood.2023023096","volume":"143","author":"J Othman","year":"2024","unstructured":"Othman J, Potter N, Ivey A, Jovanovic J, Runglall M, Freeman SD, et al. Postinduction molecular MRD identifies patients with NPM1 AML who benefit from allogeneic transplant in first remission. Blood. 2024;143:1931\u20136. https:\/\/doi.org\/10.1182\/blood.2023023096.","journal-title":"Blood"},{"key":"4744_CR14","doi-asserted-by":"publisher","first-page":"1766","DOI":"10.1200\/JCO.23.02474","volume":"42","author":"MJ Levis","year":"2024","unstructured":"Levis MJ, Hamadani M, Logan B, Jones RJ, Singh AK, Litzow M, et al. Gilteritinib as post-transplant maintenance for AML with internal tandem duplication mutation of FLT3. J Clin Oncol. 2024;42:1766\u201375. https:\/\/doi.org\/10.1200\/JCO.23.02474.","journal-title":"J Clin Oncol"},{"key":"4744_CR15","doi-asserted-by":"publisher","first-page":"1233","DOI":"10.1007\/s00277-016-2706-y","volume":"95","author":"X-D Mo","year":"2016","unstructured":"Mo X-D, Qin Y-Z, Zhang X-H, Xu L-P, Wang Y, Yan C-H, et al. Minimal residual disease monitoring and preemptive immunotherapy in myelodysplastic syndrome after allogeneic hematopoietic stem cell transplantation. Ann Hematol. 2016;95:1233\u201340. https:\/\/doi.org\/10.1007\/s00277-016-2706-y.","journal-title":"Ann Hematol"},{"key":"4744_CR16","doi-asserted-by":"publisher","first-page":"460","DOI":"10.1016\/j.bbmt.2014.11.008","volume":"21","author":"J-H Yoon","year":"2015","unstructured":"Yoon J-H, Jeon Y-W, Yahng S-A, Shin S-H, Lee S-E, Cho B-S, et al. Wilms tumor gene 1 expression as a predictive marker for relapse and survival after hematopoietic stem cell transplantation for myelodysplastic syndromes. Biol Blood Marrow Transplant. 2015;21:460\u20137. https:\/\/doi.org\/10.1016\/j.bbmt.2014.11.008.","journal-title":"Biol Blood Marrow Transplant"},{"key":"4744_CR17","doi-asserted-by":"publisher","unstructured":"Cloos J, Valk PJM, Thiede C, D\u00f6hner K, Roboz GJ, Wood BL, et al. 2025 update on MRD in acute myeloid leukemia: a consensus document from the ELN-DAVID MRD Working Party. Blood. 2025;:blood.2025031480. https:\/\/doi.org\/10.1182\/blood.2025031480.","DOI":"10.1182\/blood.2025031480"},{"key":"4744_CR18","doi-asserted-by":"publisher","first-page":"2407","DOI":"10.1182\/blood.2022016567","volume":"140","author":"S Loo","year":"2022","unstructured":"Loo S, Dillon R, Ivey A, Anstee NS, Othman J, Tiong IS, et al. Pretransplant FLT3-ITD MRD assessed by high-sensitivity PCR-NGS determines posttransplant clinical outcome. Blood. 2022;140:2407\u201311. https:\/\/doi.org\/10.1182\/blood.2022016567.","journal-title":"Blood"},{"key":"4744_CR19","doi-asserted-by":"publisher","first-page":"1345","DOI":"10.1182\/blood.2022016867","volume":"140","author":"H D\u00f6hner","year":"2022","unstructured":"D\u00f6hner H, Wei AH, Appelbaum FR, Craddock C, DiNardo CD, Dombret H, et al. Diagnosis and management of AML in adults: 2022 recommendations from an international expert panel on behalf of the ELN. Blood. 2022;140:1345\u201377. https:\/\/doi.org\/10.1182\/blood.2022016867.","journal-title":"Blood"},{"key":"4744_CR20","doi-asserted-by":"publisher","first-page":"44","DOI":"10.1007\/s11096-014-0036-5","volume":"37","author":"X Cai","year":"2015","unstructured":"Cai X, Wei J, He Y, Yang D, Jiang E, Huang Y, et al. A modified busulfan and cyclophosphamide preparative regimen for allogeneic transplantation in myeloid malignancies. Int J Clin Pharm. 2015;37:44\u201352. https:\/\/doi.org\/10.1007\/s11096-014-0036-5.","journal-title":"Int J Clin Pharm"},{"key":"4744_CR21","doi-asserted-by":"publisher","first-page":"503","DOI":"10.6004\/jnccn.2023.0025","volume":"21","author":"DA Pollyea","year":"2023","unstructured":"Pollyea DA, Altman JK, Assi R, Bixby D, Fathi AT, Foran JM, et al. Acute myeloid leukemia, version 3.2023, NCCN clinical practice guidelines in oncology. J Natl Compr Canc Netw. 2023;21:503\u201313. https:\/\/doi.org\/10.6004\/jnccn.2023.0025.","journal-title":"J Natl Compr Canc Netw"},{"issue":"19","key":"4744_CR22","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2024025154","volume":"145","author":"MJ Levis","year":"2025","unstructured":"Levis MJ, Hamadani M, Logan BR, Jones RJ, Singh AK, Litzow MR, et al. Measurable residual disease and posttransplantation gilteritinib maintenance for patients with FLT3-ITD-mutated AML. Blood. 2025;blood.2024025154. https:\/\/doi.org\/10.1182\/blood.2024025154.","journal-title":"Blood"},{"key":"4744_CR23","doi-asserted-by":"publisher","first-page":"2993","DOI":"10.1200\/JCO.19.03345","volume":"38","author":"A Burchert","year":"2020","unstructured":"Burchert A, Bug G, Fritz LV, Finke J, Stelljes M, R\u00f6llig C, et al. Sorafenib maintenance after allogeneic hematopoietic stem cell transplantation for acute myeloid leukemia with FLT3-internal tandem duplication mutation (SORMAIN). J Clin Oncol. 2020;38:2993\u20133002. https:\/\/doi.org\/10.1200\/JCO.19.03345.","journal-title":"J Clin Oncol"},{"key":"4744_CR24","doi-asserted-by":"publisher","first-page":"1144","DOI":"10.1111\/bjh.18800","volume":"201","author":"S Yokoyama","year":"2023","unstructured":"Yokoyama S, Onozawa M, Yoshida S, Miyashita N, Kimura H, Takahashi S, et al. Subclinical minute FLT3-ITD clone can be detected in clinically FLT3-ITD-negative acute myeloid leukaemia at diagnosis. Br J Haematol. 2023;201:1144\u201352. https:\/\/doi.org\/10.1111\/bjh.18800.","journal-title":"Br J Haematol"},{"key":"4744_CR25","doi-asserted-by":"publisher","first-page":"3091","DOI":"10.1038\/s41409-021-01475-8","volume":"56","author":"EC Liang","year":"2021","unstructured":"Liang EC, Chen C, Lu R, Mannis GN, Muffly L. Measurable residual disease status and FLT3 inhibitor therapy in patients with FLT3-ITD mutated AML following allogeneic hematopoietic cell transplantation. Bone Marrow Transplant. 2021;56:3091\u20133. https:\/\/doi.org\/10.1038\/s41409-021-01475-8.","journal-title":"Bone Marrow Transplant"},{"key":"4744_CR26","doi-asserted-by":"publisher","first-page":"745","DOI":"10.1001\/jama.2023.1363","volume":"329","author":"LW Dillon","year":"2023","unstructured":"Dillon LW, Gui G, Page KM, Ravindra N, Wong ZC, Andrew G, et al. DNA sequencing to detect residual disease in adults with acute myeloid leukemia prior to hematopoietic cell transplant. JAMA. 2023;329:745\u201355. https:\/\/doi.org\/10.1001\/jama.2023.1363.","journal-title":"JAMA"},{"key":"4744_CR27","doi-asserted-by":"publisher","first-page":"1813","DOI":"10.1182\/blood-2013-06-506725","volume":"122","author":"RB Walter","year":"2013","unstructured":"Walter RB, Buckley SA, Pagel JM, Wood BL, Storer BE, Sandmaier BM, et al. Significance of minimal residual disease before myeloablative allogeneic hematopoietic cell transplantation for AML in first and second complete remission. Blood. 2013;122:1813\u201321. https:\/\/doi.org\/10.1182\/blood-2013-06-506725.","journal-title":"Blood"},{"key":"4744_CR28","doi-asserted-by":"publisher","first-page":"1456","DOI":"10.1038\/leu.2016.46","volume":"30","author":"Y Zhou","year":"2016","unstructured":"Zhou Y, Othus M, Araki D, Wood BL, Radich JP, Halpern AB, et al. Pre- and post-transplant quantification of measurable (\u2018minimal\u2019) residual disease via multiparameter flow cytometry in adult acute myeloid leukemia. Leukemia. 2016;30:1456\u201364. https:\/\/doi.org\/10.1038\/leu.2016.46.","journal-title":"Leukemia"},{"key":"4744_CR29","doi-asserted-by":"publisher","first-page":"1273","DOI":"10.1200\/JCO.19.03011","volume":"38","author":"CS Hourigan","year":"2020","unstructured":"Hourigan CS, Dillon LW, Gui G, Logan BR, Fei M, Ghannam J, et al. Impact of conditioning intensity of allogeneic transplantation for acute myeloid leukemia with genomic evidence of residual disease. J Clin Oncol. 2020;38:1273\u201383. https:\/\/doi.org\/10.1200\/JCO.19.03011.","journal-title":"J Clin Oncol"},{"key":"4744_CR30","doi-asserted-by":"publisher","first-page":"1703","DOI":"10.1182\/blood-2018-02-829911","volume":"132","author":"F Thol","year":"2018","unstructured":"Thol F, Gabdoulline R, Liebich A, Klement P, Schiller J, Kandziora C, et al. Measurable residual disease monitoring by NGS before allogeneic hematopoietic cell transplantation in AML. Blood. 2018;132:1703\u201313. https:\/\/doi.org\/10.1182\/blood-2018-02-829911.","journal-title":"Blood"},{"key":"4744_CR31","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1038\/s41375-024-02458-6","volume":"39","author":"F El Chaer","year":"2025","unstructured":"El Chaer F, Perissinotti AJ, Loghavi S, Zeidan AM. Pre-emptive therapeutic decisions based on measurable residual disease status in acute myeloid leukemia: ready for prime time? Leukemia. 2025;39:1\u20137. https:\/\/doi.org\/10.1038\/s41375-024-02458-6.","journal-title":"Leukemia"},{"key":"4744_CR32","doi-asserted-by":"publisher","first-page":"558","DOI":"10.1182\/bloodadvances.2024013214","volume":"9","author":"N Ali","year":"2024","unstructured":"Ali N, Othus M, Rodr\u00edguez-Arbol\u00ed E, Orvain C, Milano F, Sandmaier BM, et al. Measurable residual disease as predictor of post\u2013day +100 relapses after allografting in adult AML. Blood Adv. 2024;9:558\u201370. https:\/\/doi.org\/10.1182\/bloodadvances.2024013214.","journal-title":"Blood Adv"},{"key":"4744_CR33","doi-asserted-by":"publisher","first-page":"1201","DOI":"10.1016\/S1470-2045(20)30455-1","volume":"21","author":"L Xuan","year":"2020","unstructured":"Xuan L, Wang Y, Huang F, Fan Z, Xu Y, Sun J, et al. Sorafenib maintenance in patients with FLT3-ITD acute myeloid leukaemia undergoing allogeneic haematopoietic stem-cell transplantation: an open-label, multicentre, randomised phase 3 trial. Lancet Oncol. 2020;21:1201\u201312. https:\/\/doi.org\/10.1016\/S1470-2045(20)30455-1.","journal-title":"Lancet Oncol"},{"key":"4744_CR34","doi-asserted-by":"publisher","first-page":"737","DOI":"10.1016\/j.immuni.2021.03.001","volume":"54","author":"G Ehx","year":"2021","unstructured":"Ehx G, Larouche J-D, Durette C, Laverdure J-P, Hesnard L, Vincent K, et al. Atypical acute myeloid leukemia-specific transcripts generate shared and immunogenic MHC class-I-associated epitopes. Immunity. 2021;54:737-752.e10. https:\/\/doi.org\/10.1016\/j.immuni.2021.03.001.","journal-title":"Immunity"},{"key":"4744_CR35","doi-asserted-by":"publisher","DOI":"10.1186\/s12967-018-1608-2","volume":"16","author":"L Handschuh","year":"2018","unstructured":"Handschuh L, Wojciechowski P, Kazmierczak M, Marcinkowska-Swojak M, Luczak M, Lewandowski K, et al. NPM1 alternative transcripts are upregulated in acute myeloid and lymphoblastic leukemia and their expression level affects patient outcome. J Transl Med. 2018;16:232. https:\/\/doi.org\/10.1186\/s12967-018-1608-2.","journal-title":"J Transl Med"},{"key":"4744_CR36","doi-asserted-by":"publisher","first-page":"1886","DOI":"10.1016\/j.molcel.2024.04.006","volume":"84","author":"S Benbarche","year":"2024","unstructured":"Benbarche S, Pineda JMB, Galvis LB, Biswas J, Liu B, Wang E, et al. GPATCH8 modulates mutant SF3B1 mis-splicing and pathogenicity in hematologic malignancies. Mol Cell. 2024;84:1886-1903.e10. https:\/\/doi.org\/10.1016\/j.molcel.2024.04.006.","journal-title":"Mol Cell"},{"key":"4744_CR37","doi-asserted-by":"publisher","DOI":"10.4143\/crt.2025.377","author":"S Jung","year":"2025","unstructured":"Jung S, Kim J-W, Han B. Uncovering putative causal non-coding RNAs in acute and chronic myeloid leukemia: a genome-wide Mendelian randomization study. Cancer Res Treat. 2025. https:\/\/doi.org\/10.4143\/crt.2025.377.","journal-title":"Cancer Res Treat"},{"key":"4744_CR38","doi-asserted-by":"publisher","first-page":"573","DOI":"10.1038\/leu.2016.271","volume":"31","author":"J Vijayakrishnan","year":"2017","unstructured":"Vijayakrishnan J, Kumar R, Henrion MYR, Moorman AV, Rachakonda PS, Hosen I, et al. A genome-wide association study identifies risk loci for childhood acute lymphoblastic leukemia at 10q26.13 and 12q23.1. Leukemia. 2017;31:573\u20139. https:\/\/doi.org\/10.1038\/leu.2016.271.","journal-title":"Leukemia"}],"container-title":["BMC Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12916-026-04744-9","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12916-026-04744-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12916-026-04744-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,8]],"date-time":"2026-04-08T11:49:54Z","timestamp":1775648994000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1186\/s12916-026-04744-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,3,3]]},"references-count":38,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["4744"],"URL":"https:\/\/doi.org\/10.1186\/s12916-026-04744-9","relation":{},"ISSN":["1741-7015"],"issn-type":[{"value":"1741-7015","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,3,3]]},"assertion":[{"value":"13 November 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 February 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 March 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This project was approved by the IHCAMS Clinical Research Academic Committee and IHCAMS Ethics Committee (IIT2021007-EC-1). All patients were included in the National Longitudinal Cohort of Hematological Diseases (NCT04645199) and provided informed consent for clinical information for scientific research at the time of their first admission.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"209"}}